24.03.2025
Luther Rechtsanwaltsgesellschaft has provided comprehensive advice to the hVIVO Group, a leading global provider of clinical trials and laboratory services, on the acquisition of two clinical research units (CRUs) of CRS Clinical Research Services Management GmbH (‘CRS’) in Germany. The acquisition of CRS Clinical Research Services Kiel GmbH and CRS Clinical Research Services Mannheim GmbH was successfully completed on 28 January 2025.
CRS is a Germany-based full-service CRO specialising in early-stage clinical development. The acquisition further expands hVIVO's presence in Germany and Europe and strengthens its position in (early-stage) clinical research across various therapeutic areas. The two new research units are a perfect strategic fit for hVIVO's existing portfolio and expand the range of specialised services.
Luther provided financial and tax advice throughout the transaction and conducted the due diligence. The team, led by Andreas Kloyer, also assisted in negotiating the purchase agreement.
About hVIVO:
hVIVO plc (AIM: HVO) is a fast-growing specialist contract research organisation and the world leader in testing infectious and respiratory disease vaccines and therapeutics using human challenge clinical trials. The Group provides end-to-end early clinical development services to its large, established and growing repeat client base, which includes four of the top 10 largest global biopharma companies.
For Luther:
Corporate/M&A: Dr Andreas Kloyer (Partner, lead), Dr Thorsten Becker (Counsel), Anne Biebler (Senior Associate), Lida Karra (ciate),
Employment: Hans-Christian Ackermann (Partner), Lukas Paetzold (Senior Associate)
Tax law: Nicole Fröhlich (partner), Ramona Hubracht (counsel), LL.M. Taxation, Konrad Prokop, LL.M. (associate)
Real estate: Ruth-Maria Eva Thomsen (partner), Maria Marinez (associate)
Facebook 
Linkedin 
XING 
Youtube